Tenaya Therapeutics (TNYA) Operating Expenses (2020 - 2026)

Tenaya Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $20.3 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 26.32% year-over-year to $20.3 million in Q1 2026; TTM through Mar 2026 was $86.1 million, a 21.55% decrease from a year earlier, with the FY2025 full-year figure at $93.3 million, down 19.51% from the prior year.
• Operating Expenses slipped to $20.3 million in Q1 2026 per TNYA's latest filing, from $20.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $35.1 million in Q2 2023 and bottomed at $20.3 million in Q1 2026.
• The 5-year median for Operating Expenses is $30.8 million (2024), against an average of $28.6 million.
• Across the five-year window, Operating Expenses jumped 137.73% in 2022 and fell 26.32% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $34.6 million in 2022, then retreated by 8.98% to $31.4 million in 2023, then slipped by 21.61% to $24.7 million in 2024, then decreased by 15.73% to $20.8 million in 2025, then slipped by 2.33% to $20.3 million in 2026.
• Per Business Quant, the three latest TNYA Operating Expenses figures stand at $20.3 million (Q1 2026), $20.8 million (Q4 2025), and $20.9 million (Q3 2025).